Investigation With BiopH+Psoriasis Medical Bath in Subject With Mild to Moderate Plaque Psoriasis.
NCT ID: NCT05046899
Last Updated: 2022-10-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
25 participants
INTERVENTIONAL
2021-09-14
2022-06-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis
NCT02462083
An Open-Label Study to Assess Safety
NCT03645499
Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment
NCT00574249
An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
NCT02326298
A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00570986
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BIOpH+ Psoriasis Medical Bath
BIOpH+ Psoriasis Medical Bath is bath. Each bath will take 20 minutes and number of bath during the entire study period is approximately 35 baths.
BIOpH+ Psoriasis Medical Bath
20 min bath every day during 1 week and thereafter 20 min bath every second day for additional 7 weeks.
Comparative device
Comparative device is Cetaphil Moisturizing Lotion. The lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.
Cetaphil Moisturizing Lotion
Cetaphil Moisturizing Lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BIOpH+ Psoriasis Medical Bath
20 min bath every day during 1 week and thereafter 20 min bath every second day for additional 7 weeks.
Cetaphil Moisturizing Lotion
Cetaphil Moisturizing Lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Males and females ≥ 18 years of age
* In the Investigator's opinion, the patient is not likely to become pregnant during study participation (e.g. in a same-sex relationship, not sexually active, sterile, not of child-bearing age, uses contraception, etc.)
* Subject diagnosed with stable mild-moderate plaque psoriasis, defined by PASI ≤ 9
* Intra-individual difference between left and right hemi-body PASI scores not \> 1.0
* Patients with symmetrical psoriasis
Exclusion Criteria
* Use of systemic/biological treatment for psoriasis
* Known hypersensitivity or allergy to study products
* Any serious medical condition that could interfere with the evaluation of study results
* Poor compliance in other investigational study, as assessed by investigator
* Pregnant, breastfeeding, or planning to become pregnant during study
* Patients with alcohol -or drug abuse
* Any other conditions as judged by the investigator may make the follow-up or investigation inappropriate
* Anyone unsuitable to participate as subject according to the Declaration of Helsinki
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biocool AB
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martin Lundvall, MD
Role: PRINCIPAL_INVESTIGATOR
Research Unit, University Hospital Örebro, Sweden
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Avdelningen för klinisk prövning
Örebro, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BioC002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.